News and Conferences
Page 12 of 16
-
UK scientists at Transpharmation and Clerkenwell Health combine lab and human trials, as psilocybin offers hope for people with an end-of-life diagnosis
UK scientists are aligning human and lab experiments in researching the potential of magic mushrooms to boost the effects of talking therapies to ease depression in people who are dealing with end-of-life diagnoses.The pre-clinical laboratory studies will be carried out by the team at Kent-headquartered contract research organisation (CRO) Transpharmation, in partnership with human clinical trials led by London-based specialist psychedelic clinical research organisation Clerkenwell Health. -
FENS Regional Meeting (FRM) - 25-27 August 2021
The FENS Regional Meeting (25-27 August 2021) is jointly organised by the Polish Neuroscience Society and the Lithuanian Neuroscience Association and will take place as an online meeting. Head of Transpharmation Poland, Ewa Sokolowska, will be presenting recent work based on the following abstract, “The effect of the second generation ofantipsychotic risperidone on aggressive behaviour in male CD-1 mice” on each day of this meeting 1-2 pm CEST,(central European summer time).
-
InterVivo Solutions Provides Update on Cooperative Psychedelics Evaluation Platform (COPE)
Drs. Inés De Lannoy and Lilia Magomedova to Lead Bioanalytical Platform Development -
31st Annual International Cannabinoid Research Society (ICRS) Virtual Symposium on Cannabinoids - 21-24 June 2021
The ICRS is dedicated to scientific research in all fields of the cannabinoids, ranging from biochemical, chemical, and physiological studies.
Transpharmation has a poster 'Investigating NLRP3-inhibitory potential of CBD' on display at this symposium during the daily poster sessions. It will be made available to you in the publications page of this website after the event.
-
Transpharmation Ireland gains Green Labs certification
Achieving more sustainable laboratory practices is important to us, and the Green Labs Certification is a recognised measure of progress towards a zero carbon future. The program provides scientists and the teams that support laboratories with actionable ways to make meaningful change. Gaining this certification is meaningful in other ways too; enhancing lab health and safety, increasing employee engagement, achieving efficiencies and preventing unnecessary energy and water waste. Transpharmation Ireland has achieved the standard required for Green Labs certification. -
Transpharmation’s pain expertise recognised
“Comorbidity of chronic pain and mood disorders: breaking the vicious cycle” This is the aim of HaPpY and we are thrilled to have been invited to join as well-known experts in this therapeutic area. HaPpY has assembled a world-class team of behavioural neuroscientists, electrophysiologists, molecular biologists, neuropharmacologists and clinicians specialising in pain and/or mood disorders from academic research labs and hospitals along with experts of the non-academic sector specialising in new instrumentation and technology, drug development and scientific promotion and communication. We can’t wait to get started. For details of all our pain and mood disorders preclinical areas please see our pain pages. -
Let us inspire you!
CEO Mark Duxon will take part in the next OBN Digital Event: ‘Building an Innovative Life Sciences Company' kindly hosted by Discovery Park - Sandwich, Kent, UK on Wednesday 12 May BST 1pm-2pm.Tickets are complimentary for OBN Members and Discovery Park Associates, with a nominal fee of £25+VAT for Non-Members - simply click here for all the details and to book http://ow.ly/YZT750ErJsk.As an entrepreneur, working to turn your innovation into reality can be hugely challenging, with many unexpected twists and turns along the way. However a great deal can be learnt from fellow entrepreneurs, including how to identify and make the most of opportunities and using challenges to further strengthen your growing business. We hope that you can join us for this event when you will hear first-hand from founders of four companies based at Discovery Park, who will share insight into the key challenges they have faced and overcome, along with key learnings they would pass on to fellow founders and business leaders. Please do invest one hour of your time, come and be inspired. -
ICNMD – 16th International Congress on Neuromuscular Diseases Digital 2021 - 21-22 & 28-29 May 2021
The ICNMD International Congress on Neuromuscular Diseases is organized on behalf of the Neuromuscular Disorders Applied Research Group of the World Federation of Neurology.
The aim of the ICNMD Congresses is to offer participants an updated view on neuromuscular disorders as well as networking opportunities to increase their international experience and collaborations. Given our involvement in the BIND-Horizon Grant we look forward to hearing about the latest developments in this area.
-
SMi - 21st Annual Conference Pain Therapeutics Virtual conference - 10-11 of May 2021
The 21st Annual Conference will provide insights into cutting edge drug discovery science, preclinical development trends and will explore novel pain drug targets and novel biomarkers, including how industry is working to overcome the challenges of opioid-based treatment.
Transpharmation will be hosting round table talks on both days. Inflammation Pain Lead Ana Pereira will be discussing Translational endpoints for Preclinical Pain at 1pm on 10th May, Neuropathic Pain Lead Daniel Cohn will be discussing Novel Pharmacological approach in Pain Therapy at 11.20am on 11th May. We are also hosting ‘meet the team’ sessions at 11.20am and 4.30pm on the 10th May and 1.35pm on the 11th May. We hope to see you there.
To view our presentation click here https://youtu.be/eqM1_l8-sEI
-
HubXchange's US East Coast CNS Therapeutics e-Xchange Virtual meeting - 24-26 May 2021
With preclinical – clinical transition being the largest failure risk in CNS therapeutics development, join us at hubXchange’s CNS Therapeutics East Coast Virtual roundtable meeting, where senior drug developers from pharma and biotech share experiences and discuss the future research landscape.
Join us at 13.00 EST to hear Transpharmation’s Scientific Lead Sandor Kantor present ‘Changes in Brain Oscillatory Activity Might Predict the Efficacy of Therapeutics in Neuropsychiatric Disorders’.
Page 12 of 16
Want to see our latest study results?
Sign up for our newsletter.
Newsletters
- What's Next in CNS Drug Discovery? Five Studies Worth Exploring
- Advancing Science Through In Vivo Refinement and Innovation - Examples from Abuse Liability and Impulsivity Screening
- Building Confidence in Decision Making
- Welcome to Reading, UK
- The Next Leap in Translational Neuroscience
- Expanding Scientific Possibility
- 2025 Was A Year of Momentum: Science, People and Partners
- 2025 Was A Year of Momentum: Science, People and Partners
- Seven Posters, One Goal: Driving Neuroscience Forward
- Advancing Preclinical Science for Next-Gen Therapies
- New Capabilities Coming Online
- Discover What's New at Transpharmation
- Unlock the Microbiome: Transform Health with Transpharmation's Advanced Studies
- Experimental Autoimmune Encephalomyelitis (EAE): Maximising The Therapeutic Efficacy of Fingolimod
- Cross-Species Epilepsy Research: Revealing the Potential of the Zebrafish Model
- Monoamine depletion to induce chronic allodynia and behavioural changes: a model of fibromyalgia
- Take your R&D pipeline into the AI era with Moseq (Motion Sequencing), our new behavioural machine-learning assay!
- Canine Microbiome
- Oral Health: Not just for Humans
- Novel Object Recognition: A Reliable Assay for Addressing Cognitive Impairments in Schizophrenia
- Pre-pulse Inhibition: A Promising Screening Tool for Novel Compounds
- Natural and induced models of osteoarthritis in Beagle dogs
- Utilizing Rapid Screening Tests to Assess the Antidepressant Potential of Psychedelic Analogues
- Long-term antidepressant effect of ketamine and psilocybin in the Chronic Social Defeat stress model
- Diabetes and Metabolic Syndrome
- Transpharmation's Animal Health Services
- Longevity Research Goes to the Dogs
- Transpharmation's Cutting-Edge Antiepileptic Drug Screening: A Global Solution for Advancing Epilepsy Research
- PTZ-treated Zebrafish provide a high throughput platform for screening novel anti-epileptic drugs
- Beyond Seizures: Epilepsy Comorbidities Explored in Mouse Kindling Studies
- Novelty-suppressed feeding and novelty-induced hypophagia: exploring sex differences and response to diazepam in C57BL/6J mice.
- Development & validation of intrathecal dosing in rats and mice
- Transpharmation's Mouse-EEG capability reveals cross-species effects of novel antidepressants ketamine and psilocybin
- Oral Health: Not just for Humans...
- Accelerate Your Diabetes Drug Development with Transpharmation's Dog Diabetes Models
- Introducing our new data analysis service for tremor-plate signals!
- Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
- New validated pre-clinical model to assess treatments for post-surgical pain
- Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
- New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
- Do Your Compounds Exhibit Anti-Inflammatory Compounds
- Profile your anti-inflammatory compounds in primary human immune cells
- New EEG services from Transpharmation. Read on for results...
- Accelerate your Drug Discovery Research. Proven results, fast and cost effective
- Urgent Treatments Needed for Parkinson's Disease
- Poor bioavailability, is the liver or intestine to blame?
- Laser Doppler; new validated protocols revealed.
- Epilepsy models leading the way. Read on for results.
- Profiling anti-inflammatory drugs; from rodent to human
- The Mismatch Negativity Challenge
- Accelerate your drug discovery research. Proven science based results cost-effectively.
- Anxiety. Three preclinical tests; data revealed...
- Seven new posters, presented at SfN, now available to view.
- Name change announcement! News from the CEO.
- Chronic fatigue: different etiologies influence translational models
- Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
- Translational value increased with non-evoked pain measures.
- Rapid access to PK non-rodent studies. Leading expertise.
- Essential tremor research
- Can a psychedelic experience be modelled in rats?
- Gender Differences in Pain. New research revealed!
- New data on the effect of single dose psilocybin!
- From ketamine to psychedelics, join our webinar starting tomorrow!
- Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
- Accreditation awarded with flying colours
- Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
- Take a look! New posters, nine therapeutic areas available to view now.
- Nine new compelling studies to be revealed at SfN21!
- Can changes in EEG improve neuropathic pain treatments?
- 40Hz ASSR: sounds that change our thoughts about schizophrenia
- Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
- Translational endpoints for preclinical pain - improving your chances.
- Transpharmation aims for global standard. Let's talk about lab sustainability.
- Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
- Psilocybin: the power of mental reorganisation
- Expansion to world class premises
- Multiple therapeutic indications
- Focus on pain
- Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
- Announcing Transpharmation Poland!